Experienced in Ovarian Carcinosarcoma

Dr. Thomas S. Stanton

Hematology Oncology | Hematology | Oncology
110 Lynch Creek Way Ste A, 
Petaluma, CA 
Experienced in Ovarian Carcinosarcoma
110 Lynch Creek Way Ste A, 
Petaluma, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Thomas Stanton is a Hematologist Oncology specialist and a Hematologist in Petaluma, California. Dr. Stanton is rated as an Experienced provider by MediFind in the treatment of Ovarian Carcinosarcoma. His top areas of expertise are Breast Cancer, Childhood Iron Deficiency Anemia, Paget Disease of the Breast, and Prostate Cancer.

His clinical research consists of participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in CA
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

110 Lynch Creek Way Ste A, Petaluma, CA 94954

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Multi-Center, Open-Label, Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anticancer Activity of Fruquintinib in Patients With Advanced Solid Tumors
A Multi-Center, Open-Label, Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anticancer Activity of Fruquintinib in Patients With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: September 25, 2024
Intervention Type: Drug
Study Drug: Fruquintinib
Study Phase: Phase 1
A Randomized, Double-blind, Adaptive, Phase II/III Study of GSK3359609 or Placebo in Combination With Pembrolizumab for First-Line Treatment of PD-L1 Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
A Randomized, Double-blind, Adaptive, Phase II/III Study of GSK3359609 or Placebo in Combination With Pembrolizumab for First-Line Treatment of PD-L1 Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Enrollment Status: Terminated
Publish Date: July 10, 2024
Intervention Type: Drug
Study Drugs: Feladilimab, Pembrolizumab
Study Phase: Phase 3
Tomivosertib (eFT-508) in Combination With PD-1/PD-L1 Inhibitor Therapy: A Study of Subjects Administered Anti-PD-1/Anti-PD-L1 Therapy That Are Experiencing Insufficient Response to Checkpoint Inhibitor Alone
Tomivosertib (eFT-508) in Combination With PD-1/PD-L1 Inhibitor Therapy: A Study of Subjects Administered Anti-PD-1/Anti-PD-L1 Therapy That Are Experiencing Insufficient Response to Checkpoint Inhibitor Alone
Enrollment Status: Completed
Publish Date: March 22, 2023
Intervention Type: Drug
Study Phase: Phase 2
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial Comparing CB-839 in Combination With Cabozantinib (CB-Cabo) vs. Placebo With Cabozantinib (Pbo-Cabo) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial Comparing CB-839 in Combination With Cabozantinib (CB-Cabo) vs. Placebo With Cabozantinib (Pbo-Cabo) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
Enrollment Status: Completed
Publish Date: March 20, 2023
Intervention Type: Drug
Study Drugs: CB-839, Cabozantinib
Study Phase: Phase 2
An Open Label, Multi-center Protocol for U.S. Patients Enrolled in a Study of Ribociclib With Endocrine Therapy as an Adjuvant Treatment in Patients With Hormone Receptor-positive, HER2-negative, High Risk Early Breast Cancer
An Open Label, Multi-center Protocol for U.S. Patients Enrolled in a Study of Ribociclib With Endocrine Therapy as an Adjuvant Treatment in Patients With Hormone Receptor-positive, HER2-negative, High Risk Early Breast Cancer
Enrollment Status: Completed
Publish Date: October 11, 2021
Intervention Type: Drug
Study Phase: Phase 2
View 4 Less Clinical Trials
Similar Doctors
Distinguished in Ovarian Carcinosarcoma
Dr. Caroline M. Behler
Hematology Oncology | Hematology | Oncology
Distinguished in Ovarian Carcinosarcoma
Dr. Caroline M. Behler
Hematology Oncology | Hematology | Oncology

Pacific Hematology Oncology Assoc.

2100 Webster St, 
San Francisco, CA 
 (31.5 miles away)
415-923-3012
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Caroline Behler is a Hematologist Oncology specialist and a Hematologist in San Francisco, California. Dr. Behler is rated as a Distinguished provider by MediFind in the treatment of Ovarian Carcinosarcoma. Her top areas of expertise are Ovarian Carcinosarcoma, Virilizing Ovarian Tumor, Testicular Yolk Sac Tumor, Bone Marrow Aspiration, and Gamma Knife Radiosurgery.

Distinguished in Ovarian Carcinosarcoma
Dr. Rishi Sawhney
Oncology | Hematology Oncology
Distinguished in Ovarian Carcinosarcoma
Dr. Rishi Sawhney
Oncology | Hematology Oncology

Stanford Health Care

300 Pasteur Dr, 
Stanford, CA 
 (59.2 miles away)
650-723-4000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Rishi Sawhney is an Oncologist and a Hematologist Oncology provider in Stanford, California. Dr. Sawhney is rated as a Distinguished provider by MediFind in the treatment of Ovarian Carcinosarcoma. His top areas of expertise are Inflammatory Breast Cancer, Paget Disease of the Breast, Angiosarcoma, and Iron Deficiency Anemia.

Distinguished in Ovarian Carcinosarcoma
Dr. Lesley C. Martin
Hematology Oncology | Hematology | Oncology
Distinguished in Ovarian Carcinosarcoma
Dr. Lesley C. Martin
Hematology Oncology | Hematology | Oncology

John Muir Physician Network

2571 Park Ave, 
Concord, CA 
 (33.3 miles away)
925-674-2100
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Lesley Martin is a Hematologist Oncology specialist and a Hematologist in Concord, California. Dr. Martin is rated as a Distinguished provider by MediFind in the treatment of Ovarian Carcinosarcoma. Her top areas of expertise are Paget Disease of the Breast, Breast Cancer, Pleuropulmonary Blastoma, and Lung Cancer.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Stanton's expertise for a condition
ConditionClose
      View All 68 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile